7 results on '"Solenn Le-Guennec"'
Search Results
2. Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
- Author
-
Fredrik Schjesvold, Paul G. Richardson, Thierry Facon, Adrián Alegre, Andrew Spencer, Artur Jurczyszyn, Kazutaka Sunami, Laurent Frenzel, Chang-Ki Min, Sophie Guillonneau, Peggy L. Lin, Solenn Le-Guennec, Frank Campana, Helgi van de Velde, Samira Bensfia, and Sara Bringhen
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2022
- Full Text
- View/download PDF
3. Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
- Author
-
Fredrik H. Schjesvold, Paul G. Richardson, Thierry Facon, Adrián Alegre, Andrew Spencer, Artur Jurczyszyn, Kazutaka Sunami, Laurent Frenzel, Chang-Ki Min, Sophie Guillonneau, Peggy L. Lin, Solenn Le-Guennec, Frank Campana, Helgi van de Velde, Samira Bensfia, and Sara Bringhen
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2020
- Full Text
- View/download PDF
4. Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma
- Author
-
Greg Finn, Frank Campana, Miles Prince, Sandrine Macé, Paul G. Richardson, Solenn Le-Guennec, Cyrille Hulin, Alexandra Tavernier, Adrian Alegre, Meral Beksac, Marie-Claude Rouchon, Ivan Spicka, Hugh J. Goodman, Stéphane Muccio, and UAM. Departamento de Medicina
- Subjects
medicine.medical_specialty ,Medicina ,medicine.medical_treatment ,Antibodies, Monoclonal, Humanized ,Dexamethasone ,Internal medicine ,Correspondence ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Multiple myeloma ,RC254-282 ,Isatuximab ,Hematology ,biology ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Immunotherapy ,Middle Aged ,medicine.disease ,Pomalidomide ,Minimal residual disease ,Thalidomide ,Oncology ,biology.protein ,Cancer research ,Randomized controlled trials ,Tumour immunology ,Antibody ,business ,Multiple Myeloma ,medicine.drug - Abstract
The ICARIA-MM study was sponsored by Sanofi. The authors thank, Helgi van de Velde, Valérie Boutet, Shujia Dai, Deborah DiNoto, Graziella Engelvin, Olivier Fedeli, Sébastien Hugla, Dominique Mouret, Béatrice Pradeilles, and Alain Roccon, all employees of Sanofi, for their contribution to the study, technology, and comments on the manuscript. The authors thank the participating patients and their families, and the study centers and investigators, for their contributions to the study. The medical writing support was provided by John Clarke, PhD and Stephanie Brillhart, PhD of Elevate Medical Affairs, contracted by Sanofi Genzyme for publication support services.
- Published
- 2021
5. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis
- Author
-
Lotfi Benboubker, Paul G. Richardson, Krzysztof Warzocha, Lionel Karlin, Vladimir Maisnar, Vladimir Vorobyev, Michel Pavic, Filiz Vural, Solenn Le Guennec, Ludek Pour, Sara Bringhen, Youngil Koh, Fatima Menas, Helgi van de Velde, and Frank Campana
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Population ,Subgroup analysis ,Antibodies, Monoclonal, Humanized ,Gastroenterology ,Dexamethasone ,Disease-Free Survival ,Relapsed ,03 medical and health sciences ,0302 clinical medicine ,Refractory ,Multiple myeloma ,Internal medicine ,Daratumumab ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Prospective Studies ,education ,Aged ,Aged, 80 and over ,Isatuximab ,education.field_of_study ,Hematology ,business.industry ,anti-CD38 monoclonal antibody ,Middle Aged ,medicine.disease ,Pomalidomide ,Criteria ,Thalidomide ,Survival Rate ,Oncology ,030220 oncology & carcinogenesis ,Female ,Prior lines ,business ,Sar650984 ,030215 immunology ,medicine.drug - Abstract
Patients with relapsed/refractory multiple myeloma (RRMM) experience several relapses, and become refractory to successive therapies. In the ICARIA-MM trial (NCT02990338), isatuximab plus pomalidomide-dexamethasone prolonged median progression-free survival (PFS) in patients with RRMM. This subgroup analysis of ICARIA-MM assessed the treatment benefit of isatuximab by prior lines of therapy and refractory status. A total of 307 patients were randomized to isatuximab-pomalidomide-dexamethasone (n = 154) or pomalidomide-dexamethasone (n = 153). Isatuximab (10 mg/kg intravenously) was given weekly in the first 28-day cycle, then every other week. Standard pomalidomide-dexamethasone doses were given. PFS was assessed by prior lines and refractory status. Overall, 102 (66 %) patients receiving isatuximab-pomalidomide-dexamethasone and 101 (66 %) patients receiving pomalidomide-dexamethasone had received 2–3 prior lines; 52 (34 %) and 52 (34 %) had received >3 prior lines, respectively. Median PFS was higher with isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone for patients who received 2–3 prior lines of therapy (12.3 vs. 7.8 months) and >3 prior lines of therapy (9.4 vs. 4.3 months). Median PFS was higher with isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone for patients who were lenalidomide-refractory (11.4 vs. 5.6 months), lenalidomide-refractory at last line (11.6 vs. 5.7 months), refractory to a proteasome inhibitor (PI) (11.4 vs. 5.6 months), and double-refractory (11.2 vs. 4.8 months). Overall response rate (ORR) in patients receiving isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone was 59.0 % versus 31.4 % in lenalidomide-refractory; 60.2 % versus 32.2 % in PI-refractory; and 58.6 % versus 29.9 % in double-refractory patients. Isatuximab-pomalidomide-dexamethasone improved PFS and ORR regardless of prior lines of therapy or refractory status, consistent with the benefit in the overall population. © 2021 The Authors, Amgen Bristol-Myers Squibb, BMS Pfizer Roche Sanofi Celgene Takeda Pharmaceutical Company, TPC Janssen Pharmaceuticals, SB reports honoraria from Amgen, Bristol-Myers Squibb, Celgene, and Janssen; and reports a consultancy/advisory role for Celgene, Janssen, Karyopharm, and Takeda. VV reports a consultancy/advisory role for Astellas, Biocad, Bristol-Myers Squibb, Janssen, Roche, Sanofi, and Takeda. VM reports a consultancy/advisory role for Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda. LK reports honoraria from Amgen, Celgene, Janssen, and Takeda; a consultancy/advisory role for Amgen, Celgene, Janssen, and Takeda; and travel support from Amgen and Janssen. MP reports honoraria from Celgene, Pfizer, and Takeda; consultancy/advisory role for Amgen, Celgene, Janssen, Roche, and Takeda; and research funding from Amgen, Celgene, Janssen, Pfizer, Roche, and Takeda. PGR reports a consultancy/advisory role for Amgen, Janssen, Karyopharm, Oncopeptides, Sanofi, and Takeda; and research funding from Bristol-Myers Squibb, Celgene, Oncopeptides, and Takeda. LP, FV, KW, LB, and YK have no disclosures. FC, SLG, FM, and HvdV are employees of Sanofi., The ICARIA-MM study was sponsored by Sanofi . The authors thank the participating patients and their families, and the study centers and investigators for their contributions to the study. Medical writing support was provided by Stephanie Brillhart, Julian Ball, and Smitha Reddy of Elevate Medical Affairs E (Fairfield, CT, USA), and funded by Sanofi (Cambridge, MA, USA).
- Published
- 2021
6. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- Author
-
Michel Attal, Paul G Richardson, S Vincent Rajkumar, Jesus San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A Dimopoulos, Jeffrey Shang-Yi Huang, Jiri Minarik, Michele Cavo, H Miles Prince, Sandrine Macé, Kathryn P Corzo, Frank Campana, Solenn Le-Guennec, Franck Dubin, Kenneth C Anderson, Paul G. Richardson, Vincent Rajkumar, Meletios A. Dimopoulos, H. Miles Prince, Kathryn P. Corzo, Kenneth C. Anderson, Simon Harrison, Wojt Janowski, Ian Kerridge, Andrew Spencer, Michel Delforge, Karel Fostier, Philip Vlummens, Ka Lung Wu, Richard Leblanc, Michel Pavic, Michael Sebag, Roman Hajek, Vladimir Maisnar, Ludek Pour, Henrik Gregersen, Lotfi Benbouker, Denis Caillot, Martine Escoffre-Barbe, Thierry Facon, Laurent Frenzel, Cyrille Hulin, Lionel Karlin, Brigitte Kolb, Brigitte Pegourie, Aurore Perrot, Mourad Tiab, Laure Vincent, Dietger Niederwieser, Achilles Anagnostopoulos, Sosana Delimpasi, Marie-Christine Kyrtsonis, Anargyros Symeonidis, Arpad Illes, Gabor Mikala, Zsolt Nagy, Sara Bringen, Paolo Corradini, Ciceri Fabio, Roberto Lemoli, Anna Liberati, Chiara Nozzoli, Renato Zambello, Shinsuke Iida, Takashi Ikeda, Satoshi Iyama, Morio Matsumoto, Chihiro Shimazaki, Kazutaka Sunami, Kenshi Suzuki, Michihiro Uchiyama, Youngil Koh, Kihyun Kim, Jae Hoon Lee, Chang-Ki Min, Hillary Blacklock, Hugh Goodman, Annette Neylon, David Simpson, Sebastian Grosicki, Artur Jurczyszyn, Adam Walter-Croneck, Krzysztof Warzocha, Luis Araujo, Claudia Moreira, Vadim Doronin, Larisa Mendeleeva, Vladimir Vorobyev, Andrej Vranovsky, Adrian Alegre, Mercedes Gironella, Marta Sonia Gonzalez Perez, Carmen Montes, Enrique Ocio, Paula Rodriguez, Mats Hardling, Birgitta Lauri, Ming-Chung Wang, Su-Peng Yeh, Mutlu Arat, Fatih Demirkan, Zafer Gulbas, Sevgi Kalayoglu Besisik, Ihsan Karadogan, Tulin Tuglular, Ali Unal, Filiz Vural, Jonathan Sive, Matthew Streetly, Kwee Yong, Jason Tache, Attal, Michel, Richardson, Paul G, Rajkumar, S Vincent, San-Miguel, Jesu, Beksac, Meral, Spicka, Ivan, Leleu, Xavier, Schjesvold, Fredrik, Moreau, Philippe, Dimopoulos, Meletios A, Huang, Jeffrey Shang-Yi, Minarik, Jiri, Cavo, Michele, Prince, H Mile, Macé, Sandrine, Corzo, Kathryn P, Campana, Frank, Le-Guennec, Solenn, Dubin, Franck, Anderson, Kenneth C, and ICARIA-MM study group
- Subjects
Male ,medicine.medical_specialty ,Asia ,030204 cardiovascular system & hematology ,Antibodies, Monoclonal, Humanized ,Gastroenterology ,Antibodies ,Dexamethasone ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Monoclonal ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Humans ,030212 general & internal medicine ,Progression-free survival ,Aged ,Antibodies, Monoclonal ,Europe ,Female ,Middle Aged ,Multiple Myeloma ,Neoplasm Recurrence, Local ,North America ,Progression-Free Survival ,Thalidomide ,Treatment Outcome ,Multiple myeloma ,Lenalidomide ,Isatuximab ,business.industry ,Bortezomib ,General Medicine ,Pomalidomide ,medicine.disease ,Neoplasm Recurrence ,Local ,business ,Isatuximab, pomalidomide, low-dose dexamethasone ,medicine.drug - Abstract
BACKGROUND: Isatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous phase 1b study, around 65% of patients with relapsed and refractory multiple myeloma achieved an overall response with a combination of isatuximab with pomalidomide and low-dose dexamethasone. The aim of this study was to determine the progression-free survival benefit of isatuximab plus pomalidomide and dexamethasone compared with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma. METHODS: We did a randomised, multicentre, open-label, phase 3 study at 102 hospitals in 24 countries in Europe, North America, and the Asia-Pacific regions. Eligible participants were adult patients with relapsed and refractory multiple myeloma who had received at least two previous lines of treatment, including lenalidomide and a proteasome inhibitor. Patients were excluded if they were refractory to previous treatment with an anti-CD38 monoclonal antibody. We randomly assigned patients (1:1) to either isatuximab 10 mg/kg plus pomalidomide 4 mg plus dexamethasone 40 mg (20 mg for patients aged ≥75 years), or pomalidomide 4 mg plus dexamethasone 40 mg. Randomisation was done using interactive response technology and stratified according to the number of previous lines of treatment (2-3 vs >3) and age (
- Published
- 2019
7. P-0288 - Aflibercept/Folfiri vs Placebo/Folfiri in Metastatic Colorectal Cancer: A Post-Hoc Analysis of Median Overall Survival in Velour from the Retrospectively Assessed Time of Starting First-Line Treatment
- Author
-
Josep, Tabernero, Teresa, Macarulla, Yves, Humblet, Albert, ten Tije, Hendrik, Kroening, Cristina, Grávalos, Solenn, Le-Guennec, Emmanuelle, Dochy, and Eric, Van Cutsem
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.